PTIX on OTC

Protagenic Therapeutics, Inc.\new

Annual Report on Form 10-K. The below summary is qualified in its entirety by that more complete discussion of such risks and uncertainties.⁵ From its latest annual report

Price unavailable

Last updated Oct 19, 2026.

Overview

$0Revenue, fiscal 2026³

$1.4MNet income, fiscal 2026³

Compare with another stock.

TickerPTIX on OTC²
IndustryPharmaceutical Preparations²
HeadquartersWilmington, United States²
Incorporated inDE⁴
Business address149 Fifth Avenue, Suite 500, New York, Ny 10010⁴
Filer categoryNon-accelerated filer, Smaller reporting company⁴
Legal formCorporation²
LEI549300KPBYAVJLPDKB70²
StatusActive²
LEI statusLapsed (not renewed)²
Registered addressc/o CORPORATION SERVICE COMPANY, 251 LITTLE FALLS DRIVE, 19808 Wilmington, United States²
Registered withDivision of Corporations, Department of State, 2375531²

See how the biggest companies compare on our leaderboards

Annual Report on Form 10-K. The below summary is qualified in its entirety by that more complete discussion of such risks and uncertainties.⁵ From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2026

52.2%Return on equity³

Financial statements

Revenue⁶⁷⁸⁹³$0 in 2026

Operating income¹⁰⁶⁷⁸⁹³-$4.5M in 2026+116% since 2019

Net income¹⁰⁶⁷⁸⁹³$1.4M in 2026

Every line of the income statement as filed: the last 2 fiscal years, latest first.³

Period ending	2026-03-31	2025-03-31
Accounting and audit fees	$272.6K	$132.6K
Research and Development	$901.9K	$376.7K
Legal Fees	$874.4K	$183.1K
Consulting Fees	$939.2K	$667.6K
Salaries and wages	$764.6K	$132.8K
Bad debt expense		$1.0M
General and administrative - other	$332.4K	$77.5K
Stock compensation	$418.6K
TOTAL OPERATING EXPENSES	$4.5M	$2.6M
LOSS FROM OPERATIONS	-$4.5M	-$2.6M
Interest expenses	-$1.5M	-$1.0M
Derivative expense	-$343.4K
Change in fair value of derivative liabilities	$1.5M
Foreign currency exchange differences	$9.3K	$41.1K
Gain/loss on disposal of subsidiary	$7.3M
Gain/loss on extinguishment of debt	-$1.1M
TOTAL OTHER INCOME (EXPENSE)	$5.9M	-$998.3K
INCOME (LOSS) BEFORE INCOME TAXES	$1.4M	-$3.6M
Basic	$0.59	-$0.67
Diluted	$0.59	-$0.67
Basic	2.3M shares	5.4M shares
Diluted	2.3M shares	5.4M shares
Net income (loss)	$1.4M	-$3.6M
Unrealized foreign currency translation loss	-$202.1K	-$27.5K
Shares issued in connection with Phytanix Bio purchase	-$130.0K
Comprehensive income (loss)	$1.0M	-$3.6M

Total assets¹⁰⁶⁷⁸⁹³$3.7M in 2026+333% since 2019

Total liabilities¹⁰⁶⁷⁸⁹³$1.0M in 2026−30% since 2019

Shareholders’ equity⁶⁷⁸⁹³$2.6M in 2026

Cash¹⁰³$1.5M in 2026+89% since 2019

Every line of the balance sheet as filed: the last 3 fiscal years (annual) or 3 quarters (quarterly), latest first.³

Period ending	2026-03-31	2025-03-31	2024-03-31
Cash in bank	$1.5M	$14.5K
Prepaid expenses	$33.4K
VAT receivable		$73.5K
Inventories		$1.0K
Total current assets	$1.5M	$89.1K
Fixed assets, net	$14.6K
Intangible assets, net	$2.1M
Total long-term assets	$2.1M
Total Assets	$3.7M	$89.1K
Notes payable, net		$1.7M
Accounts payable	$949.5K	$961.1K
Accrued liabilities	$82.0K	$249.1K
Derivative liabilities		$1.4M
Loans payable, related parties		$779.2K
Total current liabilities	$1.0M	$5.0M
Total liabilities	$1.0M	$5.0M
Common stock, $0.0001 par value, respectively; 100,000,000 authorized; 1,810,208 and 5,800,000 shares issued outstanding	$182
Additional paid in capital	$7.0M	$455.7K
Accumulated deficit	-$4.0M	-$5.4M
Foreign currency translation adjustment	-$343.1K	-$11.0K
Total stockholders equity (deficit)	$2.6M	-$5.0M	-$1.8M
Total liabilities and stockholders equity (deficit)	$3.7M	$89.1K
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	2.0M shares	2.0M shares
Preferred stock, shares issued	0 shares	0 shares
Preferred stock, shares outstanding	0 shares	0 shares
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	100.0M shares	100.0M shares
Common stock, shares issued	1.8M shares	5.8M shares
Common stock, shares outstanding	1.8M shares	5.8M shares

Period ending	2026-03-31	2025-03-31	2024-03-31
Cash in bank	$1.5M	$14.5K
Prepaid expenses	$33.4K
VAT receivable		$73.5K
Inventories		$1.0K
Total current assets	$1.5M	$89.1K
Fixed assets, net	$14.6K
Intangible assets, net	$2.1M
Total long-term assets	$2.1M
Total Assets	$3.7M	$89.1K
Notes payable, net		$1.7M
Accounts payable	$949.5K	$961.1K
Accrued liabilities	$82.0K	$249.1K
Derivative liabilities		$1.4M
Loans payable, related parties		$779.2K
Total current liabilities	$1.0M	$5.0M
Total liabilities	$1.0M	$5.0M
Common stock, $0.0001 par value, respectively; 100,000,000 authorized; 1,810,208 and 5,800,000 shares issued outstanding	$182
Additional paid in capital	$7.0M	$455.7K
Accumulated deficit	-$4.0M	-$5.4M
Foreign currency translation adjustment	-$343.1K	-$11.0K
Total stockholders equity (deficit)	$2.6M	-$5.0M	-$1.8M
Total liabilities and stockholders equity (deficit)	$3.7M	$89.1K
Preferred stock, par value	$0.00	$0.00
Preferred stock, shares authorized	2.0M shares	2.0M shares
Preferred stock, shares issued	0 shares	0 shares
Preferred stock, shares outstanding	0 shares	0 shares
Common stock, par value	$0.00	$0.00
Common stock, shares authorized	100.0M shares	100.0M shares
Common stock, shares issued	1.8M shares	5.8M shares
Common stock, shares outstanding	1.8M shares	5.8M shares

Cash from operations¹⁰⁶⁷⁸⁹³-$2.8M in 2026+475% since 2019

Every line of the cash flow as filed: the last 2 fiscal years, latest first.³

Period ending	2026-03-31	2025-03-31
Net income (loss)	$1.4M	-$3.6M
Amortization of debt discount to interest expense	$1.6M	$598.8K
Stock based compensation	$418.6K
Warrants and stock issued for services		$103.2K
Bad debt expense		$773.2K
Derivative expense	$343.4K
Change in fair value of derivative liabilities	-$1.5M
Depreciation expense	$49.2K
Gain/loss on disposal of subsidiary	-$7.3M
Gain/loss on extinguishment of debt	$1.1M
Inventories	-$26	-$29
Prepaid expenses	$53.4K
VAT receivable	$37.7K	-$40.4K
Accounts payable	$1.0M	$182.1K
Accrued liabilities	$17.4K	$206.0K
Net cash used in operating activities	-$2.8M	-$1.8M
Cash received in acquisition of Phytanix Bio	$943.2K
Cash spent on unwind of Phytanix Bio acquisition	-$310.0K
Purchase of fixed assets	-$3.3K
Net cash provided by investing activities	$629.9K
Increase in note payable for acquisition of Phytanix Bio	-$533.9K
Net proceeds from notes payable		$1.6M
Proceeds from sale of common stock	$395.5K	$200
Proceeds from exercise of warrants	$3.9M
Proceeds from related party loans	$62.3K	$187.1K
Net cash provided by financing activities	$3.9M	$1.8M
NET INCREASE IN CASH	$1.7M	$40.4K
Effect of exchange rate adjustments on cash	-$202.1K	-$27.5K
Bifurcation of warrants as derivative liabilities		$1.3M
Debt extinguishment - related party parent reflected as capital contribution		$410.8K
Net assets acquired of Phytanix Bio, net of cash paid	$1.4M
Shares issued for warrant exercises	$3.9M

Compare Protagenic Therapeutics, Inc.\new with another company

Leadership

Who has led Protagenic Therapeutics, Inc.\new, and when. Pick a name to see everywhere that person has worked.

Chief executive

Chair

Garo H. Armen2017–now

President

Chief financial officer

Chief operating officer

2010201520202025

Chief executive officerBarrett Evans Oct 24, 2025 to now¹⁴
Chief executive officerEdward J. Gildea Sep 12, 2014 to Sep 12, 2014¹⁵
Chief executive officerJeffrey A. Schwartz Jan 29, 2010 to Jan 29, 2010¹⁶
Chief executive officerBurton Katz Feb 22, 2007 to Jun 30, 2009¹⁷
ChairGaro H. Armen Oct 18, 2017 to now¹⁸
PresidentRobert Ziroyan Feb 17, 2016 to Feb 17, 2016¹⁹
PresidentAndrew Stollman Feb 7, 2008 to Jun 30, 2009²⁰
PresidentRaymond Musci Feb 22, 2007 to Feb 22, 2007²¹
Chief financial officerAlexander K. Arrow Feb 17, 2016 to Mar 29, 2024²²
Chief financial officerDavid J. Horin Sep 12, 2014 to Sep 12, 2014²³
Chief financial officerNathan Yu-Gai Fong Sep 20, 2011 to Sep 20, 2011²⁴
Chief financial officerThomas Plotts Jan 6, 2010 to Jul 2, 2010²⁵
Chief financial officerDaniel Harvey Feb 7, 2008 to Feb 7, 2008²⁶
Chief financial officerAndrew Zaref Jul 29, 2008 to Jun 30, 2009²⁷
Chief financial officerAllan Legator Feb 22, 2007 to Jan 31, 2008²⁸
Chief financial officerRobert S. Ellin Nov 7, 2006 to Nov 7, 2006²⁹
Chief operating officerRobert Ziroyan Feb 17, 2016 to Feb 17, 2016¹⁹
Chief operating officerSusan Swenson Aug 29, 2007 to Feb 13, 2008³⁰
Chief operating officerRobert S. Ellin Nov 7, 2006 to Nov 7, 2006²⁹

Board members and other officers (29)

OfficerGaro H. Armen Feb 17, 2016 to Aug 18, 2016³¹
Chief Marketing OfficerSharon Siegel Jun 7, 2011 to Jun 7, 2011³²
Exec VP, Corporate DevelopmentRaymond Musci Dec 15, 2010 to Dec 17, 2010³³
Chief Technology OfficerZachary Greenberger May 11, 2009 to Jun 30, 2009³⁴
Chief Marketing OfficerScott Walker Feb 22, 2007 to Mar 12, 2007³⁵
OfficerJay Wolf Nov 7, 2006 to Nov 7, 2006²⁹
Board memberBarrett Evans Oct 24, 2025 to now¹⁴
Board memberJennifer Buell Jul 21, 2020 to Mar 29, 2024³⁶
Board memberBrian Corvese Oct 18, 2017 to Mar 29, 2024³⁷
Board memberGaro H. Armen Feb 17, 2016 to Aug 18, 2016³¹
Board memberGregory Ekizian Feb 17, 2016 to Jun 22, 2016³⁸
Board memberKhalil Barrage Feb 17, 2016 to Mar 29, 2024³⁹
Board memberEdward J. Gildea Sep 12, 2014 to Sep 12, 2014¹⁵
Board memberJonathan Schechter Sep 12, 2014 to Sep 12, 2014⁴⁰
Board memberStuart Goldfarb Jan 20, 2010 to Jan 20, 2010⁴¹
Board memberAndrew Stollman Feb 7, 2008 to Aug 7, 2008²⁰
Board memberLawrence Burstein Feb 7, 2008 to Sep 30, 2010⁴²
Board memberRobert Machinist Feb 7, 2008 to Feb 7, 2008⁴³
Board memberJeffrey A. Schwartz Nov 20, 2008 to Jan 29, 2010⁴⁴
Board memberMark Dyne Nov 21, 2008 to Sep 30, 2010⁴⁵
Board memberBurton Katz Feb 22, 2007 to Jun 30, 2009¹⁷
Board memberDrew Larner Feb 22, 2007 to Mar 6, 2007⁴⁶
Board memberRaymond Musci Feb 22, 2007 to Dec 17, 2010²¹
Board memberGil Klier Aug 15, 2007 to Sep 27, 2007⁴⁷
Board memberIsaac Kier Oct 26, 2006 to Oct 26, 2006⁴⁸
Board memberJerome A. Chazen Oct 27, 2006 to Sep 30, 2010⁴⁹
Board memberBarry Regenstein Nov 7, 2006 to Mar 7, 2007⁵⁰
Board memberJay Wolf Nov 7, 2006 to Nov 7, 2006²⁹
Board memberRobert S. Ellin Nov 7, 2006 to Sep 30, 2010²⁹

Former names

Atrinsic, Inc.Jun 30, 2009 to Jun 20, 2016⁴
NEW MOTION, INC.May 7, 2007 to Jun 30, 2009⁴
MPLC, Inc.Jun 10, 2005 to Apr 2, 2007⁴
MILLBROOK PRESS INCDec 6, 1996 to May 23, 2005⁴

Timeline

Oct 24, 2025New chief executive Barrett Evans becomes CEO¹⁴
Sep 12, 2014New chief executive Edward J. Gildea becomes CEO¹⁵
Jan 29, 2010New chief executive Jeffrey A. Schwartz becomes CEO¹⁶
Feb 22, 2007New chief executive Burton Katz becomes CEO¹⁷
Feb 3, 1994Founded Protagenic Therapeutics, Inc.\new is founded²

Filings

122 filings to the SEC since October 2021: 8 annual reports, 15 quarterly reports, 43 major events, 17 insider forms, 8 large holders, 31 other. The latest 20:

Aug 24, 20264 EDGAR
Aug 20, 20264 EDGAR
Aug 20, 20268-K EDGAR
Aug 20, 20264 EDGAR
Aug 19, 202610-Q EDGAR
Aug 14, 2026NT 10-Q EDGAR
Aug 14, 202610-K EDGAR
Aug 12, 20264 EDGAR
Aug 10, 20264 EDGAR
Aug 6, 20264 EDGAR
Aug 3, 20264 EDGAR
Jun 30, 2026NT 10-K EDGAR
Apr 7, 20268-K EDGAR
Mar 9, 202610-Q EDGAR
Mar 3, 20268-K EDGAR
Feb 24, 20268-K EDGAR
Feb 18, 2026NT 10-Q EDGAR
Jan 23, 202625-NSE EDGAR
Jan 5, 20268-K EDGAR
Dec 5, 2025DEF 14A EDGAR

The 122 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

10 open-market trades by officers, directors and large owners since October 2021: 10 buys and 0 sales. Grants, option exercises and gifts are left out.

Date	Who	Trade	Shares	Price	Value	Filing
Aug 21, 2026	ARMEN GARO HEXEC. CHAIR & PRINCIPAL OFF	Buy	20,000	$0.65	$13.0K	Form 4
Aug 20, 2026	ARMEN GARO HEXEC. CHAIR & PRINCIPAL OFF	Buy	16,634	$0.59	$9.8K	Form 4
Aug 19, 2026	ARMEN GARO HEXEC. CHAIR & PRINCIPAL OFF	Buy	2,700	$0.35	$945	Form 4
Aug 11, 2026	ARMEN GARO HEXEC. CHAIR & PRINCIPAL OFF	Buy	2,220	$0.32	$710	Form 4
Aug 6, 2026	ARMEN GARO HEXEC. CHAIR & PRINCIPAL OFF	Buy	685	$0.22	$151	Form 4
Aug 5, 2026	ARMEN GARO HEXEC. CHAIR & PRINCIPAL OFF	Buy	5,000	$0.26	$1.3K	Form 4
Jul 30, 2026	ARMEN GARO HEXEC. CHAIR & PRINCIPAL OFF	Buy	26,291	$0.18	$4.7K	Form 4
Oct 12, 2023	Arrow Alexander K.Chief Financial Officer	Buy	8,000	$0.81	$6.5K	Form 4
May 18, 2022	Arrow Alexander K.Chief Financial Officer	Buy	8,000	$0.72	$5.8K	Form 4
May 17, 2022	Arrow Alexander K.Chief Financial Officer	Buy	23,000	$0.71	$16.3K	Form 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

BIGGER CAPITAL FUND L PSCHEDULE 13G/A, 2 filings Jul 8, 2025 to Aug 25, 2025⁵¹
ARMISTICE CAPITAL, LLCSCHEDULE 13G/A, 5 filings Feb 15, 2022 to Feb 14, 2025⁵²
Hudson Bay Capital Management LPSC 13G/A, 1 filing Feb 4, 2022⁵³

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026. Change is in shares since the quarter before.

Fund	Shares	Value	Share of the fund	Change
DRW Securities, LLC	41,783	$16.4K	0.0%	No change

13F reports cover disclosed long positions in U.S. stocks only.

Sources

The numbers on this page point here. Each one links to the record it came from.

1
SEC EDGARProtagenic Therapeutics, Inc.\new filings on SEC EDGAR
2
GLEIFProtagenic Therapeutics, Inc.\new LEI record (549300KPBYAVJLPDKB70)
3
SEC EDGARProtagenic Therapeutics, Inc.\new 10-K for fiscal 2026
4
SEC EDGARProtagenic Therapeutics, Inc.\new filings on SEC EDGAR
5
SEC EDGARProtagenic Therapeutics, Inc.\new annual report, Item 1 (Business)
6
SEC EDGARProtagenic Therapeutics, Inc.\new 10-K for fiscal 2020
7
SEC EDGARProtagenic Therapeutics, Inc.\new 10-K for fiscal 2021
8
SEC EDGARProtagenic Therapeutics, Inc.\new 10-K for fiscal 2022
9
SEC EDGARProtagenic Therapeutics, Inc.\new 10-K for fiscal 2023
10
SEC EDGARProtagenic Therapeutics, Inc.\new 10-K for fiscal 2019
11
SEC EDGARProtagenic Therapeutics, Inc.\new 10-Q for fiscal 2025
12
SEC EDGARProtagenic Therapeutics, Inc.\new 10-Q for fiscal 2025
13
SEC EDGARProtagenic Therapeutics, Inc.\new 10-Q for fiscal 2026
14
SEC EDGARBarrett Evans, Chief executive officer
15
SEC EDGAREdward J. Gildea, Chief executive officer
16
SEC EDGARJeffrey A. Schwartz, Chief executive officer
17
SEC EDGARBurton Katz, Chief executive officer
18
SEC EDGARGaro H. Armen, Chair
19
SEC EDGARRobert Ziroyan, President
20
SEC EDGARAndrew Stollman, President
21
SEC EDGARRaymond Musci, President
22
SEC EDGARAlexander K. Arrow, Chief financial officer
23
SEC EDGARDavid J. Horin, Chief financial officer
24
SEC EDGARNathan Yu-Gai Fong, Chief financial officer
25
SEC EDGARThomas Plotts, Chief financial officer
26
SEC EDGARDaniel Harvey, Chief financial officer
27
SEC EDGARAndrew Zaref, Chief financial officer
28
SEC EDGARAllan Legator, Chief financial officer
29
SEC EDGARRobert S. Ellin, Chief financial officer
30
SEC EDGARSusan Swenson, Chief operating officer
31
SEC EDGARGaro H. Armen, Officer
32
SEC EDGARSharon Siegel, Chief Marketing Officer
33
SEC EDGARRaymond Musci, Exec VP, Corporate Development
34
SEC EDGARZachary Greenberger, Chief Technology Officer
35
SEC EDGARScott Walker, Chief Marketing Officer
36
SEC EDGARJennifer Buell, Board member
37
SEC EDGARBrian Corvese, Board member
38
SEC EDGARGregory Ekizian, Board member
39
SEC EDGARKhalil Barrage, Board member
40
SEC EDGARJonathan Schechter, Board member
41
SEC EDGARStuart Goldfarb, Board member
42
SEC EDGARLawrence Burstein, Board member
43
SEC EDGARRobert Machinist, Board member
44
SEC EDGARJeffrey A. Schwartz, Board member
45
SEC EDGARMark Dyne, Board member
46
SEC EDGARDrew Larner, Board member
47
SEC EDGARGil Klier, Board member
48
SEC EDGARIsaac Kier, Board member
49
SEC EDGARJerome A. Chazen, Board member
50
SEC EDGARBarry Regenstein, Board member
51
SEC EDGARBIGGER CAPITAL FUND L P SCHEDULE 13G/A on Protagenic Therapeutics, Inc.\new
52
SEC EDGARARMISTICE CAPITAL, LLC SCHEDULE 13G/A on Protagenic Therapeutics, Inc.\new
53
SEC EDGARHudson Bay Capital Management LP SC 13G/A on Protagenic Therapeutics, Inc.\new